RYE, N.Y., Oct. 11 /PRNewswire/ — Dr. Joan Fallon, founder and
CEO of Curemark, LLC, (www.curemark.com), a drug
research and development company focused on the treatment of
neurological diseases, moderated the neuroscience roundtable
focused on autism at the Life Sciences Summit 2010, held September
22-23 in Hauppauge, New York.
Sponsored by the State University of New York at Stony Brook,
Brookhaven National Laboratories and Cold Spring Harbor
Laboratories, the Life Sciences Summit focused on forging
partnerships between biopharmaceutical companies and companies
emerging from academia to accelerate biomedical solutions in areas
including infectious disease, neuroscience, oncology and
regenerative medicine. In addition to serving as panel
moderator, Dr. Fallon presented an update on Curemark’s autism
treatment CM-AT, currently in Phase III
clinical trials, at the conference’s Emerging Company and
Innovator’s Showcase.
“The Life Sciences Summit brought together researchers,
scientists and representatives of companies working at the
forefront of new medical developments, who shared and exchanged
ideas in this very conducive forum. The discussion at the
Roundtable highlighted some of the latest research in identifying
possible causes of autism as well promising new therapies,” she
said.
Participating at the Roundtable entitled “Autism Spectrum
Disorder: Recent Advances in the Development of Symptomatic
Treatments” were Joseph Buxbaum, PhD, MSc, principal investigator,
Laboratory of Molecular Neuropsychiatry, Mount Sinai School of
Medicine; Deborah A. Pearson, PhD, professor, Division of Child and
Adolescent Psychiatry, Department of Psychiatry and Behavioral
Sciences, University of Texas Medical School at Houston; John
Spiro, PhD, senior associate director for research, Simons
Foundation; and Larry J.
‘/>”/>
SOURCE